All posts tagged Thomas Flaig

  • Trial shows responses to abiraterone acetate in some prostate cancer patients with initial hormone induction failure

    In trial results, 13 percent of metastatic prostate cancer patients deemed “hormone refractory” did, in fact, have strong responses to treatment with the next-generation hormonal drug abiraterone acetate.

Harry Peterson, CU Cancer Center